Next Article in Journal
Biopsy on Progression in Patients with EGFR Mutation–Positive Advanced Non-Small-Cell Lung Cancer—A Canadian Experience
Previous Article in Journal
Does Free nicotine Replacement Improve Smoking Cessation Rates in Cancer Patients?
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 27
Issue 1
10.3747/co.27.5401
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Acceptability of Anal Cancer Screening Tests for Women Living with HIV in the EVVA Study

by
E. Kaufman
1,2,
C. de Castro
3,
T. Williamson
4,
B. Lessard
3,
M. Munoz
3,
M.H. Mayrand
5,
A.N. Burchell
6,7,
M.B. Klein
3,7,
L. Charest
8,
M. Auger
9,
V. Marcus
9,
F. Coutlée
3,10,
A. de Pokomandy
1,3,7,* and
the EVVA Study Group
1
Department of Family Medicine, McGill University, Montreal, QC, Canada
2
Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
3
Chronic Viral Illness Service, McGill University Health Centre–Glen Site, 1001 Decarie Boulevard, Room D02-4110, Montreal, QC H4A 3J1, Canada
4
Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
5
Départements d’obstétrique–gynécologie et de médecine sociale et préventive, Centre hospitalier de l’Université de Montréal and Université de Montréal, Montreal, QC, Canada
6
Department of Family and Community Medicine and Centre for Urban Health Solutions, St. Michael’s Hospital, and Department of Family and Community Medicine and Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada
7
Canadian Institutes of Health Research, Canadian HIV Trials Network, Vancouver, BC, Canada
8
Clinique médicale l’Actuel, Montreal, QC, Canada
9
Department of Pathology, McGill University, and McGill University Health Centre, Montreal, QC, Canada
10
Département de microbiologie, infectiologie, et immunologie, Centre hospitalier de l’Université de Montréal and Université de Montréal, Montreal, QC, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2020, 27(1), 19-26; https://doi.org/10.3747/co.27.5401
Submission received: 8 November 2019 / Revised: 5 December 2019 / Accepted: 3 January 2020 / Published: 1 February 2020

Abstract

Background: Anal cancer is potentially preventable through screening. For screening to be implemented, the screening procedures must be acceptable to the affected population. The objective of the present study was to measure the acceptability of currently available anal cancer screening tests in a population of women living with hiv who had experienced the tests. Methods: The EVVA study (“Evaluation of Human Immunodeficiency Virus, Human Papillomavirus, and Anal Intraepithelial Neoplasia in Women”) is a prospective cohort study of adult women living with HIV in Montreal, Quebec. Participants were screened with cervical or anal hpv testing and cervical or anal cytology every 6 months for 2 years. High-resolution anoscopy (HRA) and digital anal rectal examination (DARE) were also performed systematically, with biopsies, at baseline and at 2 years. An acceptability questionnaire was administered at the final visit or at study withdrawal. Results: Of 124 women who completed the acceptability questionnaire, most considered screening “an absolute necessity” in routine care for all women living with HIV [77%; 95% confidence interval (CI): 69% to 84%]. Yearly anal cytology or anal HPV testing was considered very acceptable by 81% (95% CI: 73% to 88%); HRA every 2 years was considered very acceptable by 84% (95% CI: 77% to 90%); and yearly DARE was considered very acceptable by 87% (95% CI: 79% to 92%). Acceptability increased to more than 95% with a longer proposed time interval. Pain was the main reason for lower acceptability. Conclusions: Most participating women considered anal cancer screening necessary and very acceptable. Longer screening intervals and adequate pain management could further increase the acceptability of repeated screening.
Keywords: hiv; human papillomavirus; hpv; women; anal cancer; screening acceptability; cancer prevention hiv; human papillomavirus; hpv; women; anal cancer; screening acceptability; cancer prevention

Share and Cite

MDPI and ACS Style

Kaufman, E.; de Castro, C.; Williamson, T.; Lessard, B.; Munoz, M.; Mayrand, M.H.; Burchell, A.N.; Klein, M.B.; Charest, L.; Auger, M.; et al. Acceptability of Anal Cancer Screening Tests for Women Living with HIV in the EVVA Study. Curr. Oncol. 2020, 27, 19-26. https://doi.org/10.3747/co.27.5401

AMA Style

Kaufman E, de Castro C, Williamson T, Lessard B, Munoz M, Mayrand MH, Burchell AN, Klein MB, Charest L, Auger M, et al. Acceptability of Anal Cancer Screening Tests for Women Living with HIV in the EVVA Study. Current Oncology. 2020; 27(1):19-26. https://doi.org/10.3747/co.27.5401

Chicago/Turabian Style

Kaufman, E., C. de Castro, T. Williamson, B. Lessard, M. Munoz, M.H. Mayrand, A.N. Burchell, M.B. Klein, L. Charest, M. Auger, and et al. 2020. "Acceptability of Anal Cancer Screening Tests for Women Living with HIV in the EVVA Study" Current Oncology 27, no. 1: 19-26. https://doi.org/10.3747/co.27.5401

APA Style

Kaufman, E., de Castro, C., Williamson, T., Lessard, B., Munoz, M., Mayrand, M. H., Burchell, A. N., Klein, M. B., Charest, L., Auger, M., Marcus, V., Coutlée, F., de Pokomandy, A., & , the EVVA Study Group. (2020). Acceptability of Anal Cancer Screening Tests for Women Living with HIV in the EVVA Study. Current Oncology, 27(1), 19-26. https://doi.org/10.3747/co.27.5401

Article Metrics

Back to TopTop